BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...masking their activity until they reach the tumor microenvironment (see “Werewolf Debuts to Develop Tumor-activated Biologics”).Jasper Therapeutics Inc....
...Fares as CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...Group Corp. (Tokyo:4565) spinouts (see “Medicxi’s Orexin Dream Deal” ). Jasper tops off series A Jasper Therapeutics Inc....
BioCentury | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

...and radiation therapy as a conditioning regimen to prepare patients for hematopoietic stem cell transplants. Jasper Therapeutics Inc....
...CD117) Elizabeth S. Eaton, Staff Writer Portola Pharmaceuticals Inc. Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) JSP191 Jasper Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...masking their activity until they reach the tumor microenvironment (see “Werewolf Debuts to Develop Tumor-activated Biologics”).Jasper Therapeutics Inc....
...Fares as CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...Group Corp. (Tokyo:4565) spinouts (see “Medicxi’s Orexin Dream Deal” ). Jasper tops off series A Jasper Therapeutics Inc....
BioCentury | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

...and radiation therapy as a conditioning regimen to prepare patients for hematopoietic stem cell transplants. Jasper Therapeutics Inc....
...CD117) Elizabeth S. Eaton, Staff Writer Portola Pharmaceuticals Inc. Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) JSP191 Jasper Therapeutics Inc....
Items per page:
1 - 3 of 3